news-21112024-123052

Poolbeg Pharma plc, a company focused on developing innovative medicines for diseases with high unmet medical needs, recently received a patent grant from the US Patent Office for its POLB 001 immunomodulator. This patent covers the use of POLB 001, a p38 MAP kinase inhibitor, in treating patients at risk of severe influenza and hypercytokinemia.

The granting of this patent enhances Poolbeg’s Intellectual Property portfolio, which already includes patents for p38 MAP kinase inhibitors in severe influenza treatment and POLB 001 in hypercytokinemia treatment. The company has also filed additional patent applications to expand its coverage in these areas, particularly related to cytokine release syndrome induced by cancer immunotherapies. By strengthening its IP portfolio, Poolbeg aims to increase the value and attractiveness of POLB 001 to potential partners.

Jeremy Skillington, CEO of Poolbeg Pharma, expressed his excitement about the patent grant, highlighting the importance of strong IP in the biopharmaceutical industry. He emphasized that each new patent not only protects their assets but also enhances the commercial appeal of POLB 001 for future collaborations. Skillington reaffirmed the company’s commitment to addressing critical medical needs through valuable programs and partnerships.

In addition to the recent patent grant, Poolbeg Pharma is actively pursuing partnerships and high-value programs to advance the development and commercialization of its assets. The company’s focus on innovation and addressing unmet medical needs underscores its dedication to making a meaningful impact in the healthcare industry.

Overall, the patent grant for POLB 001 marks a significant milestone for Poolbeg Pharma, signaling the company’s commitment to advancing novel treatments and building a strong foundation for future success in the biopharmaceutical sector. With a growing IP portfolio and a clear strategic focus, Poolbeg is well-positioned to make a positive difference in the lives of patients and drive innovation in the field of healthcare.